

Original Research Article

Comment [S1]:

Evaluation of anti-inflammatory activities of aqueous and ethanolic extracts of *Gomphrena celosioides* Linn.

ABSTRACT

Aims: This study was therefore aimed to evaluate potential anti-inflammatory activity of Aqueous and Ethanolic extracts of *Gomphrena celosioides* (C. Mart) and to determine the most active extract in rat.

Study Design: *Gomphrena celosioides* was collected from Bingerville, District of Abidjan (Cote d'Ivoire). The plant was identified and authenticated by the "Centre National de Floristique", University Felix Houphouet Boigny, Cocody.

Place and Duration of study: Analysis on the plant samples were done at the "Laboratoire de Pharmacodynamie-Biochimique, UFR Biosciences, Université de Cocody-Abidjan (Côte d'Ivoire), and Institut Pasteur de Côte d'Ivoire, Département de Biochimie médicale & fondamentale" between September 2013 and June 2014.

Methodology: The anti-inflammatory activities were investigated by utilizing carrageenan induced paw edema and CRP concentration in rat. These extracts were administrated intraperitoneally at different doses (100 and 200 mg/kg body weight) to rats.

Result: The present study showed a significant anti-inflammatory activity at 200 mg/kg. b.w. to both extracts which were comparable to the Diclofenac (10 mg/kg) inhibition.

However, the inflammation inhibition is raised more than 2.6 % with the ethanolic extract when this comparison is made with the aqueous extract. This study showed an increased CRP concentration ($p < 0.05$) at rats treated with carrageenan with regard to extracts and Diclofenac rats groups.

. But there is no significant difference between CRP concentration with extracts and diclofenac rats groups ($p > 0.05$).

Conclusion: This study showed that aqueous and ethanolic extracts of *Gomphrena celosioides* have a potential anti-inflammatory properties. However, this anti-inflammatory activity is more raised with ethanolic extract and seems to have the most active extract. So, ethanolic and aqueous extracts can be utilized for therapeutic purposes.

Keywords: *Gomphrena celosioides*, anti-inflammatory, carrageenan, Diclofenac, CRP

1. INTRODUCTION

Inflammation is a local response of living mammalian tissues to the injury. It is a body defense reaction in order to eliminate or limit the spread of injurious agents as well as to remove the consequent necrosed cells and tissue [1]. Inflammation standard drugs like Indomethacin, Diclofenac, Voveran, ect, have their limitation. So, it is a need to continue to research newer anti-inflammatory drugs. Medicinal plants are believed to be an important source of new chemical substances. Many herbal preparations are being prescribed widely for the treatment of inflammatory conditions [2]. The research into plants with alleged folkloric use as pain relievers, anti-inflammatory agents, should therefore be viewed as a fruitful and logical research strategy in the search for new analgesic and anti-inflammatory drugs [3].

Gomphrena celosioides Mart (Amaranthaceae) is an annual herb with popular usage in traditional medicine. In Africa, *Gomphrena celosioides* is called in traditional language Adukowé [4]. An early pharmaco-chemical study of *Gomphrena celosioides* revealed the presence of saponins, steroids, aminoacids and non-reducing sugars in all the plant parts, phenols and flavonoids in leaves, inflorescences and stem. Betacyanins occurred only in the stem; reducing sugar in the

Comment [S2]: What are the limitations ?

Comment [S3]: Consider changing to "there is "

inflorescence, while ketoses were reported found in the root and stem [5, 6]. Similar metabolites were found by de Moura *et al* [7] in this plant.

Phytochemical study of the Aqueous extract showed that this plant contains Flavonoids, Saponins, sterols and tri-terpens, tanins, coumarins, reducers compounds, sugars and holosises [8]. The ethyl acetate and methanol extracts of *Gomphrena celosioides* was phytochemically examined by Dosumu *et al.* [9,10] and revealed the presence of secondary metabolites. These metabolites include alkaloids, tannins, saponins, steroids, glycosides and reducing sugars

These different types of chemical interground Blended highlighted in extracts of this plant have therapeutic effects. It can be used for the treatment of human and animal diseases [11]. In South America, it is used as abortive [12]. Vieira [13] have demonstrated the analgesic, tonic, carminative and diuretic properties of this plant. Recently, Dosumu *et al.*, [14] reported its antimicrobial and anti-helminthic properties. Crude and ethanol extract of the leaf of the plant were found to have antioxidant/antidegradative activity [15]. But, little information was recorded on the anti-inflammatory activity of *Gomphrena celosioides*. In Africa, different plant parts are used in traditional medicine, either as powder soaked in water or ethyl alcohol, or as a toothpick to chew [16]

The present investigation was carried out to evaluate the anti-inflammatory potential of Aqueous and Ethanolic extracts of *Gomphrena celosioides* and to determine the most active extract.

2. MATERIALS AND METHODS

2.1 Samples Collection and extraction

Gomphrena celosioides plants was collected in September 2013 from Bingerville, District of Abidjan (Cote d'Ivoire). The plant was identified and authenticated by botanist of "Centre National de Floristique", University Felix Houphouet Boigny, Cocody. The authentically identified plant material (roots, leaves, flowers and stems) was washed and shade air-dried for 2-3 days in the laboratory at room temperature. It was powdered and subjected to different extraction procedures.

2.1.1 Aqueous extract

The aqueous extract was prepared by decoction method [17]. The powdered material was suspended in distilled water (100g/1000 mL) agitated with an agitator for 24h at 80°C. The extract was filtered through absorbent cotton then with Whatman N°1 filter paper to get the filtrate. The filtrate was dried under reduced pressure using a rotary flash evaporator and stored at a temperature of -4°C until use.

2.1.2 Ethanolic extract

The powder plant material (100 g) was soaked in 1L of 70% ethanol, agitated with an agitator for 24h at 80°C. The extract was filtered and concentrated to dryness using a rotary flash evaporator and stored at a temperature of -4°C until use.

2.2 Experimental animals

Wistar albinos rats weighing 180- 200 g of each sex kept for two weeks at the laboratory Animal home of the Faculty of Pharmaceutical (Biochemistry), University of Felix Houphouet Boigny, Cote d'Ivoire were used. The animals were maintained under standard housing conditions: temperature (27°± 1C), humidity (55-60%), light/dark cycle (12 :12h) and had free access to standard rodent pellet diet (products of FACL®, Côte d'Ivoire) and water *ad libitum*.

2.3 Tests for Anti-inflammatory Activity

Anti-inflammatory activity at the extracts was measured using carrageenan induced rat paw edema essay [18, 19]. Extracts of *Gomphrena* were dissolved in normal saline (0.9%) and administrated intra-peritoneally [20].

2.3.1 Carrageenan-induced paw edema model

Thirty six rats of either sex were divided into six groups (n=6). Different groups of animals were pretreated with 100 or 200 mg/kg.b.w. of each extract or 10 mg/kg.b.w. Diclofenac as reference drug [21, 22]. The control group received normal saline (0.9%). These drugs were administrated intra-peritoneally to rats. After 1h, inflammation was induced by injection of 0.2 mL [23] carrageenan (1% suspension of carrageenan in normal saline) into the plantar surface of the right hind paw. The paw diameter was measured at hourly intervals for 6 h and at 24h hours using digital paw edema meter. Percentage inhibition was calculated as follows:

$$\text{Inhibition (\%)} = \frac{(V_c - V_t) \times 100}{V_c}$$

Where V_c and V_t are average edema diameter of control and treated group respectively.

2.3.2 Quantitative measurement of Rat C Reactive Protein (CRP) in serum

Thirty rats were divided into 6 groups, each containing six animals. Group I received normal saline 0.9% (control). Group II received 0.2 ml carrageenan, a phlogistic agent. Groups III, IV and V received (200 mg/kg.b.w) aqueous and ethanolic extracts and 10 mg/kg.b.w. Diclofenac respectively. + 0.2 ml carrageenan after 1h. After 5 hr of carrageenan administration, all the animals were sacrificed and blood samples were collected and serum was separated. Serum levels of CRP(C Reactive Protein, Rat ELISA Kit, ab108827) were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit supplied by abcam®, UK, as per the manufacturer's instructions.

Essay procedure [24]

All materials and prepared reagents were equilibrated prior to use. Standards, controls and samples were prepared in duplicate. Reagents, working standards and samples were prepared and equilibrated as instructed. The assay was performed at room temperature (18-25°C). Excess microplate strips from the plate frame was removed and returned immediately to the foil pouch with desiccant inside. The pouch was resealed securely to minimize exposure to water vapor and stored in a vacuum desiccators. 50 µL of C Reactive Protein Standard or sample were added to the wells and covered with a sealing tape and incubated for two hours. The timer started after the last sample addition. The plates were washed five times with 200 µl of the wash Buffer manually and then inverted each time and the contents were decanted on absorbent paper towel to remove the liquid. 50 µL of 1X Biotinylated C Reactive Protein Antibody were added to each well and the plates were incubated for one hour. The microplates were washed as described above. 50 µL of 1X SP Conjugate were added to each well and incubated for 30 minutes. The microplates reader were turned on and the program was set up in advance. The microplates were washed as described above. 50 µL of Chromogen Substrate were added per well and incubated for about 20 minutes or till the optimal blue colour density developed. 50 µL of Stop Solution were added to each well. The color should be changed from blue to yellow. The absorbance was read on a microplate reader at a wavelength of 450 nm immediately.

2.4 Statistical Analysis

The values expressed as mean ± SEM from 6 animals. The results were subjected to statistical analysis by using one way ANOVA followed by Dunnett's test to verify the significant, P values less than 0.05 were considered significant.

3. RESULTS AND DISCUSSION

3.1 Carrageenan-induced paw edema model

The results showed a significant reduction in the paw diameter with 200 mg/kg.b.w of extracts (aqueous, ethanolic) and Diclofenac treated group, from 1sth to 24thh as compared to 100 mg/kg.b.w of the two extracts (table1). Indeed, There was a significant reduction in the paw volume observed with Diclofenac

Comment [S4]:

Comment [S5]:

Comment [S6]: If you administer drugs by ip 30minutes is sufficient interval between extract administration and oedema induction.

Comment [S7]: x ?

160 treated group from 1st h to 6th h as compared to control group. Groups treated with the extracts of
 161 Gomphrena celosioides at dose of 100 mg/kg showed significant decrease in paw edema volume from at
 162 2nd h ($p<0.05$) and 6th h ($p<0.01$) compared to control group. Groups treated with the ethanolic extract of
 163 Gomphrena celosioides at dose of 200 mg/kg showed significant decrease in paw edema volume from at
 164 2nd and, 6th h ($p<0.01$) compared to control group.

166 However, with ethanolic extract (200 mg/kg.bw) the inflammation inhibition is raised more than 2.6%
 167 when this comparison is made with the aqueous extract and 0.39% with diclofenac (Table2)..

168 Indeed , inhibition of carrageenan induced hind paw edema in rats by
 169 Diclofenac started at 1st hr and which was maintained up to 24th hr.
 170 Diclofenac at the dose of 10 mg/kg at 1st, 2nd, 3rd , 4th, 5th 6th and 24th h
 171 has shown 10.65, 20.17, 24.68, 29.65, 32.18, 32.56, and 13.46 % inhibition,
 172 respectively. At the dose of 200 mg/kg of the ethanolic extract seem have
 173 the better inhibition than diclofenac and has shown 12.85, 21.61, 25.79,
 174 30.45, 31.91, 31.46 and 13.83% inhibition, respectively from the 1st to 24th h.
 175 46.15 and 52.88% inhibition, respectively.

179 **Table 1:** Effect of Aqueous and Ethanolic extracts of Gomphrena celosioides and Diclofenac
 180 on carrageenan induced paw edema in rats

Treatment groups	Dose (mg/kg)	Edema diameter (mm)							
		0hr	1hr	2hr	3hr	4hr	5hr	6hr	24hr
Normal saline (control)	-	4.79 ± 0.11	6.38 ± 0.41	6.94 ± 0.55*	7.21 ± 0.47**	7.52 ± 0.38**	7.52 ± 0.46**	7.31 ± 0.51**	5.42 ± 0.16
Aqueous Extract	100	4.61 ± 0.09	5.57 ± 0.24	5.50 ± 0.23	5.43 ± 0.24	5.56 ± 0.35	6.20 ± 0.48	6.86 ± 0.45*	5.08 ± 0.26
Aqueous Extract	200	4.78 ± 0.15	5.75 ± 0.13	5.44 ± 0.08	5.38 ± 0.06	5.33 ± 0.06	5.26 ± 0.05	5.23 ± 0.06	5.18 ± 0.04
Ethanolic Extract	100	4.88 ± 0.05	5.88 ± 0.28	6.08 ± 0.19	6.21 ± 0.13	6.43 ± 0.25	6.78 ± 0.25*	6.54 ± 0.16 *	5.05 ± 0.18
Ethanolic Extract	200	4.59 ± 0.10	5.56 ± 0.07	5.44 ± 0.09	5.35 ± 0.10	5.23 ± 0.11	5.12 ± 0.07	5.01 ± 0.08	4.67 ± 0.05
Diclofenac (Standard)	10	4.41 ± 0.02	5.70 ± 0.03	5.54 ± 0.01	5.43 ± 0.01	5.29 ± 0.02	5.10 ± 0.02	4.93 ± 0.06	4.69 ± 0.06

182 Each value is mean ± SEM, N= 6 rats

184 The data was analyzed by using One Way ANOVA followed by Dunnett's test, ** $p<0.01$, * $p<0.05$, where
 185 Extracts and control were compared with Diclofenac

187 **Table 2:** Percentage inhibition of paw edema exhibited by aqueous and ethanolic
 188 extracts of Gomphrena celosioides and Diclofenac

Treatment	Dose mg/kg	Percentage inhibition (%) at various times intervals							Mean of % Inhibition
		1hr	2hr	3hr	4hr	5hr	6hr	24hr	
Normal saline (control)	-	-	-	-	-	-	-	-	-
Aqueous Extract	100	12.69	20.74	24.68	26.06	17.55	6.15	6.27	16.91 ± 3.59
Aqueous Extract	200	9.87	21.61	25.38	29.12	30.05	28.45	4.42	23.17 ± 3.95

Ethanollic Extract	100	7.83	12.39	13.86	14.49	9.84	10.53	6.82	11.32 ± 1.16*
Ethanollic Extract	200	12.85	21.61	25.79	30.45	31.91	31.46	13.83	25.84 ± 2.89
Diclofenac	10	10.65	20.17	24.68	29.65	32.18	32.56	13.46	25.45 ± 3.08

3.2 Effect of the two extracts and diclofenac on serum levels CRP at 5th h during carrageenan induced hind paw edema in rats.

This study showed an increased CRP concentration ($p < 0.05$) at rats treated with carrageenan with regard to extracts and Diclofenac rats groups (Figure 1). But there is no significant difference between CRP concentration with extracts and diclofenac rats groups ($p > 0.05$). finally, this anti-inflammatory activity is more raised with ethanolic extract and seems have an active effect.




Figure 1: Changes in the level of serum CRP of rats treated with aqueous extracts and diclofenac at 5th h during carrageenan induced hind paw edema in rats.

We have to determine these two extracts with the water and the alcohol to respect the working conditions of the African traditional uses. Thus, The anti-inflammatory activity of aqueous and ethanolic extracts of *Gomphrena celosioides* was evaluated by carrageenan induced rat paw edema method and determination serum level of C-reactive protein using commercial kit, according to manufacturer instructions.

In our previous studies, *Gomphrena celosioides* seems contained several agents anti-inflammatory of and result in the partial inhibition of inflammatory-mediator released. In the light of the results on the table 1 and 2, *Gomphrena celosioides* inhibits edema similarly to Diclofenac. So, anti-inflammatory activity of *Gomphrena celosioides* seemed to be effective in the two phases of acute inflammation. Therefore, the anti-inflammatory activity of *Gomphrena celosioides* may be due to inhibition of mediators of the inflammation such as histamine, serotonin released during the first phase of inflammation and prostaglandins, bradykinin, leukotrienes which released during the second phase of inflammation.

Indeed, Carrageenan induced paw edema is widely used for determining the acute phase of inflammation [25]. Carrageenan as a phlogistic agent is non antigenic and is devoid of apparent systemic effect [26]. This model is based on the principle of release of various inflammatory mediators by carrageenan [27]. Edema formation due to carrageenan in the rat paw is a biphasic [28]. The first phase is mainly due the release of histamine and serotonin in the first hour. The late phase is sustained by prostaglandin release and mediated by bradykinin, leukotrienes, polynuclear (neutrophils and monocytes) and prostaglandins produced by tissue macrophages [29,1]. Anti-inflammatory drugs inhibit different stages of inflammation [30].

C-reactive protein (CRP) is the classic acute-phase reactant and a sensitive marker for systemic inflammation. The body produces C-reactive protein or CRP during the general process of inflammation. CRP is a "marker" for inflammation, meaning its presence indicates an increased state of inflammation in the body. Measurement of CRP may provide a useful method of assessing the prognosis of disease with systemic inflammation [31].

However, The CRP synthesized by the liver cells, plays an important role in innate immunity by its properties opsonization, activation of complement and receptor binding immunoglobulins [32]. The site secretion main, but not exclusive hepatocytes is responsible for basal levels of plasma CRP. During an inflammatory response, its output increases. Secretion (extrahepatic) exists in neurons where production is increased in dementia of the Alzheimer type [33] in some cells [34], and finally even within atherosclerotic plaques [35].

Our study identifies and characterizes the direct interaction between inflammation and CRP. Indeed, treatment with aqueous and ethanolic of *Gomphrena celosioides* and diclofenac after 5 th of carrageenan administration a decreased CRP level as compared reflecting the inhibition of inflammation.

In view of these results of inhibition, we note that the ethanolic extract reduced more than the aqueous extract and is almost identical to the reference molecule. So, the average value of reduction is more than 2,6 % With regard to the reference molecule

4. CONCLUSION

The results obtained from the present study have clearly demonstrated that the extracts of *Gomphrena celosioides* possessed anti-inflammatory activities which support the traditional utilization in Africa, particularly in Côte d'Ivoire. Ethanol extract seemed more active than the aqueous extract and this activity is comparable to those obtained with reference molecules such as diclofenac.

REFERENCES

1. Anupama, A. S., Kishor, N. R., Rahul, D. K., Kanchan, S. M. Evaluation of anti-inflammatory and analgesic activities of *Tamarindus indica* Seeds. IJPSDR 2012, 4(3):213-217
2. Bagul MS, Srinivasa H, Kanaki NS, Rajani M. Antiinflammatory activity of two Ayurvedic formulations containing guggul Ind. J. Pharmacol. 2005;37:399-400

3. Gupta, M., Mazumder U.K., Gomath, P., Thamilsalvan V., Anti-inflammatory evaluation of leaves of *Plumeria acuminata*. BMC complementary and alternative medicine. 2006,6:36:1472-6882.
4. A. C. Adonou, H. Yedomonhan, B. Djossa, S. I. Legba, M. Oumorou et A. Akoegninou. Etude Ethnobotanique des plantes médicinales vendues dans le marché d'Abomey-Calavi au Bénin. *Int. J. Biol. Chem. Sci.* 6(2): 745-772. 2012
5. Botha, S. Gerritsma-Van der Vijver, L. M. 1986. Pharmacochemical study of *Gomphrena celosioides* (Amaranthaceae). *Suid-Afrikaanse Tydskrif vir Natuurw-etenskap en Tegnologie*,5(1):40-45.
6. Onocha P. A., Ajaiyeoba E. O., Dosumu O. O., Ekundayo O. Phytochemical screening and Biological Activities of *Gomphrena celosioides* (C. Mart) extracts. *Nigerian Soc. Exp. Biol. J.*, 2005., 5(2):59-65
7. de Moura RM, Pereira PS, Januário AH, França Sde C, Dias DA.. Antimicrobial screening and quantitative determination of benzoic acid derivative of *Gomprena celosioides* by TLC-densitometry. *Chem. Pharm. Bull.*, 2004,52(11): 1342-1344.
8. Maxime M. S., Bale B., Mama A. B., Jean M. A., Karim L. D.. Composition chimique de l'extrait aqueux de *Gomphrena celosioides* Mart. et étude de ses effets toxicologiques chez le foie du rat Wistar ». *Rev. ScLib Ed. Mers.*, 2012, 4, pp. 2111-4706
9. Dosumu, O.O., P.A. Onocha, E.O. Ajaiyeoba and O. Ekundayo,. Phytochemical Screening and Biological Activities of *Gomphrena celosioides* (C. Mart) Extracts. *NISEB*, 2005, 5(2): 61-67.
- 10 Muhammad Ilyas, Arsia Tarnamand Nargis Begum. Biological Potential and Phyto-pharmacological Screening of *Gomphrena* Species. *Global J. Pharmacol.*, 2013, 7 (4): 457-464.
- 11 Oladele, G. M., Abatan, M. O., Olukunle, J. O., Okediran, B. S. Anti-inflammatory and analgesic effects of aqueous leaf extracts of *Gomphrena celosioides* and *Momordica charantia*. *J. Nat. Sci. Engr. Tech.*, 2009, 8(2):1-8
12. Burkill HM..The useful plants of West Tropical Africa vol 1. Families A-D. Royal Botanical Garden kew. 1984, pp. 441-415.
13. Vieira, C.C.J., Mercier H., C hu, E.P., Figueiredo, Ribeiro, R.C.L. *Gomphrena* species (globe amaranth) in vitro culture and production of secondary metabolites. In: Bajaj, Y.P.S., ed. *Biotechnol. Agr. Forest.*: 1994, MAP VII 28: 257-270
14. Dosumu OO, Idowu PA, Onocha PA, Ekundayo O.. Isolation of 3-(4-Hydroxyphenyl) Methylpropenoate and bioactivity evaluation of *Gomphrena celosioides*. *EXCLI J.*, 2010, 9: 173-180
15. A.Meena, V.Elango Antioxidant/antidegradative effects of *Trichopus zeylanicus gaertn* and *Gomphrena celosioides* on den/hcb induced male albino rats. *JMSCR* , 2013 ,1(5):252-267.
16. Bokra A. R. ,. Etudes des effets physiologiques et pharmacodynamiques de quelques plantes utilisées dans le traitement de l'impuissance sexuelle masculine en Côte d'Ivoire. Thèse de Doctorat en pharmacie, Université d'Abidjan ; 2001, 205pp
17. ACKAH Jacques Auguste Alfred Bognan, KRA Adou Koffi Mathieu, ZIRIHI Guédé Noël et GUEDE-Guina Frédéric. Evaluation et essais d'optimisations de l'activité anticandidosique de *Terminalia catappa* LINN (TEKAM3), un extrait de combretaceae de la pharmacopée ivoirienne. *Bulletin de la Société Royale des Sciences de Liège*, 2008,77 : 120 – 136
18. Winter CA, Risely EA, Nuss GW. Carragenan-induced oedema in the hind Paw of the rats as an assay for anti-inflammatory drugs. *EBM*.1962;111: 554-547
- 19.. Chithran, A., Babu, R. T., Himaja N. Comparative study on anti-inflammatory activity of *Cyperus roduntus* (L) using different solvent system in carrageenan induced paw edema in albino wistar rats". *Int. J. PhytoPharm.* 2012, 3(2), 130-134
20. Ratheesh, M and Helen, A. Anti-inflammatory activity of *Ruta graveolens* Linn on carrageenan induced paw edema in wistar male rats. *AJB*, 2007, 5(10);1209-12111.

333
334 21. Rubina, M.; Zargar, M. A.; Latief, A. Evaluation of anti-inflammatory potential of *Atropa acuminata* in
335 carrageenan induced inflammation in rats". J. Med. Plants Res. 2012, 6(43): 5586-5592
336
337 22. Ravi, V.;Saleem, T.S.M.; Patel, S. S.; Raamamurthy, J.; Gauthaman, K. Anti-inflammatory effect of
338 Methanolic Extract of *Solanum nigrum* Linn Berries." Int. J. Appl. Res. Nat. Pro,2009,. 2(2):33-36.
339
340 23. Mahanta Bhagyashree, Kalita Jogen Chantra. Efficacy *Solanum torvum* (Berries) on carrageenan
341 induced rat paw edema model an in vivo anti-inflammatory study. IRJP, 2012, 3(1)
342
343 24. Anonyme 2014.www.abcam.com/www.abcam.cn/www.abcam.co.jp
344
345 25. Patil, P.; Prasad, K.; Nitim, M.; Vijay, K. M.; Sreenivasa R. K. Evaluation of anti-inflammatory effect of
346 *Catoptropis procero* root extract against different mediators of inflammation in albino rats.IRJP. 2011.2(3);
347 279-284
348
349 26. Chakraborty A, Devi RK, Rita S, Sharatchandra K, Singh TI. Preliminary studies on anti-inflammatory
350 and analgesic activities of *Spilanthes acmella* in experimental animal models. IJP. 2006; 36:148-150.
351
352 27. I. Igbe; G. O. Inarumen. The Effect of Leaf Aqueous Extract of *Brachystegia eurycoma* Harms
353 (Fabaceae) in Acute and Chronic Inflammatory Animal Models. B J P R, 2013,3(3): 391-400
354
355 28. Vinegar R, Truax JF, Selph JH, Johnson PR, Venable AL, McKenzie KK. Pathway to carrageenan-
356 induced inflammation in the hind limb of the rat. Fed Proc. 1987;46:118-126
357
358
359 29. Brito ARMS, Antonio M.A. Oral anti-inflammatory and antiulcerogenic activities of a hydroalcoholic
360 extract and partitioned fractions of *Turnera ulmifolia* (Turneraceae), J. Ethnopharmacol 1998,61: 215-
361 228.
362
363 30. Jyothi, M.B.; Jayanthi, M. K. ; Suresha, R.N. Evaluation of anti-inflammatory activity of *Aegle*
364 *marmelos* (Bilwa) root. I J P.2011; 43(4):393-397.
365
366 31. Zubelewicz B, Szkodzinski J, Romanowski W, Blazclois A, Dnikiewicz A, Muc wierizgon M, Szkilnik R.
367 Simvastatine decrease concentration of IL-2 in hypercholesterolemic patients after treatment for 2
368 weeks. J Biol Regul Homeost Agents. 2004;18: 295-301
369
370 32. Dupuy, M. A., Terrier, N., Sénécal, L., Morena, M., Leray, H., Canaud, B., Cristol, P. J.
371 La CRP est- elle plus qu'un marqueur de l'inflammation? Rev.Nephro. 2003,7:337-341
372
373 33. Yasojima K, Schwab C, Mc Geer EG, Mc Geer PL, Human neurons generate C-reactive protein and
374 amyloid P:Up regulation in Alzheimer disease.Brain Res 2000; 887: 80-9
375
376 34. Kuta AE, Baum LL. C-reactive protein is produced by a small number of normal human peripheral
377 blood lymphocytes. J. Exp. Med., 1986;164: 321-6
378
379 35. Yasojima K, Schwab C, Mc Geer EG, Mc Geer PL, Generation of C-reactive protein an complement
380 components in atherosclerotic plaques. Am J Pathol; 2001;158:1039-51